The five-year gift will support the building and maintenance of the NYGC's genomics infrastructure to work with its institutional founding members.
With DNA methylation data for more than 1,800 chronic lymphocytic leukemia B cells, researchers tracked CLL epimutation rates and saw lineages with distinct treatment responses.
Gencove offers low-coverage whole-genome sequencing and has developed imputation algorithms and informatics to extract useful information from the data.
The method builds on a previous technique the group developed to measure transcriptomes and surface proteins from single cells.
The researchers uncovered disease-linked genes that are expressed in certain cells and disease stages and discovered various gene expression modules.
The assay monitors mutations across a patient's genome and matches them to mutations found in a patient's resected tumor and in DNA in the bloodstream.
The ALS Association is committing $3.5 million, including a $1 million commitment from its Greater New York chapter, while the Tow Foundation is contributing $2.5 million.
While the New York Genome Center says whole-genome cancer sequencing is the future, companies already offering such tests are struggling to get paid.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
The companies will offer BGI's DNBseq next-generation sequencing technology along with Gencove's ImputeSeq low-pass sequencing analysis pipeline.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.